Home › Kanser sa Dugo
Pag-aaral pangklinika para sa Kanser sa Dugo na nagre-recruit sa U.S.
153 pag-aaral para sa Kanser sa Dugo ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX46 pag-aaral
- New York City, NY26 pag-aaral
- Boston, MA25 pag-aaral
- Washington, DC19 pag-aaral
- Baltimore, MD18 pag-aaral
- Seattle, WA18 pag-aaral
- Los Angeles, CA17 pag-aaral
- Durham, NC16 pag-aaral
- Chicago, IL15 pag-aaral
- Philadelphia, PA14 pag-aaral
- Nashville, TN13 pag-aaral
- Atlanta, GA13 pag-aaral
- Edison, NJ13 pag-aaral
- Baldwin Park, CA13 pag-aaral
- Columbus, OH13 pag-aaral
- Milwaukee, WI12 pag-aaral
- Dallas, TX12 pag-aaral
- Detroit, MI12 pag-aaral
- Minneapolis, MN11 pag-aaral
- Birmingham, AL11 pag-aaral
- Ann Arbor, MI11 pag-aaral
- Omaha, NE10 pag-aaral
- Cincinnati, OH10 pag-aaral
- St. Louis, MO10 pag-aaral
- Jacksonville, FL10 pag-aaral
- Miami, FL9 pag-aaral
- Memphis, TN9 pag-aaral
- Cedar Rapids, IA9 pag-aaral
- Denver, CO9 pag-aaral
- San Antonio, TX8 pag-aaral
- Salt Lake City, UT8 pag-aaral
- Aurora, CO8 pag-aaral
- San Francisco, CA8 pag-aaral
- Clifton, NJ8 pag-aaral
- Tampa, FL8 pag-aaral
- Buffalo, NY7 pag-aaral
- Madison, WI7 pag-aaral
- Charlotte, NC7 pag-aaral
- Grand Rapids, MI7 pag-aaral
- Phoenix, AZ7 pag-aaral
Ayos sa estado
- Alabama11 pag-aaral
- Arizona12 pag-aaral
- Arkansas5 pag-aaral
- California35 pag-aaral
- Colorado14 pag-aaral
- Connecticut8 pag-aaral
- Delaware3 pag-aaral
- District of Columbia7 pag-aaral
- Florida28 pag-aaral
- Georgia16 pag-aaral
- Illinois16 pag-aaral
- Indiana9 pag-aaral
- Iowa9 pag-aaral
- Kansas7 pag-aaral
- Kentucky10 pag-aaral
- Louisiana6 pag-aaral
- Maryland29 pag-aaral
- Massachusetts26 pag-aaral
- Michigan22 pag-aaral
- Minnesota17 pag-aaral
- Missouri11 pag-aaral
- Nebraska10 pag-aaral
- Nevada4 pag-aaral
- New Hampshire3 pag-aaral
- New Jersey21 pag-aaral
- New York29 pag-aaral
- North Carolina24 pag-aaral
- Ohio22 pag-aaral
- Oklahoma8 pag-aaral
- Oregon8 pag-aaral
- Pennsylvania21 pag-aaral
- Rhode Island4 pag-aaral
- South Carolina8 pag-aaral
- South Dakota5 pag-aaral
- Tennessee20 pag-aaral
- Texas49 pag-aaral
- Utah8 pag-aaral
- Virginia11 pag-aaral
- Washington20 pag-aaral
- West Virginia5 pag-aaral
- Wisconsin15 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 110 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05724121Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Nagre-recruitPhase 1
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06904066Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT03486873Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069Rutgers University Study of the Genetics of Blood Cancers
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 110 · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT07714044Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Nagre-recruitObservasyonal na pag-aaral
Edad 0 hanggang 38 · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06131801A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06697184A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07572006A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT04634552Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06910969Genomic Profiling in Cancer Patients
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Set 24, 2026 · NCT01775072Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Nagre-recruitMaagang Phase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06398457Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT04728893Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Nagre-recruitPhase 3
Edad 18 hanggang 71 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07504458Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT03816345Wearable Activity Tracking to Curb Hospitalizations
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT06587100Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
Nagre-recruitMaagang Phase 1
Edad 12 hanggang 80 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT04744116Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Nagre-recruitPhase 1/2Malugod na tinatanggap ang malusog na boluntaryo
Edad 12 hanggang 120 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT05470491Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
Nagre-recruitPhase 1
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07162038Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07648264Bone Marrow Imaging and Clinical Outcomes Across Hematologic, Oncologic, and Other Relevant Conditions
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Set 18, 2026 · NCT07743476Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Nagre-recruitPhase 1/2Malugod na tinatanggap ang malusog na boluntaryo
Edad 12 hanggang 120 · Lahat ng kasarian · Na-update Set 18, 2026 · NCT05327023Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04242095SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT05375643Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Nagre-recruitPhase 1
Hanggang edad 75 · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06345027Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.